Abstract:Understanding the metabolic fate of a xenobiotic substance can help inform its potential health risks and allow for the identification of signature metabolites associated with exposure. The need to characterize metabolites of poorly studied or novel substances has shifted exposure studies towards non-targeted analysis (NTA), which often aims to profile many compounds within a sample using high-resolution liquid-chromatography mass-spectrometry (LCMS). Here we evaluate the suitability of suspect screening analysis (SSA) liquid-chromatography mass-spectrometry to inform xenobiotic chemical metabolism. Given a lack of knowledge of true metabolites for most chemicals, predictive tools were used to generate potential metabolites as suspect screening lists to guide the identification of selected xenobiotic substances and their associated metabolites. Thirty-three substances were selected to represent a diverse array of pharmaceutical, agrochemical, and industrial chemicals from Environmental Protection Agency’s ToxCast chemical library. The compounds were incubated in a metabolically-active in vitro assay using primary hepatocytes and the resulting supernatant and lysate fractions were analyzed with high-resolution LCMS. Metabolites were simulated for each compound structure using software and then combined to serve as the suspect screening list. The exact masses of the predicted metabolites were then used to select LCMS features for fragmentation via tandem mass spectrometry (MS/MS). Of the starting chemicals, 12 were measured in at least one sample in either positive or negative ion mode and a subset of these were used to develop the analysis workflow. We implemented a screening level workflow for background subtraction and the incorporation of time-varying kinetics into the identification of likely metabolites. We used haloperidol as a case study to perform an in-depth analysis, which resulted in identifying five known metabolites and five molecular features that represent potential novel metabolites, two of which were assigned discrete structures based on in silico predictions. This workflow was applied to five additional test chemicals, and 15 molecular features were selected as either reported metabolites, predicted metabolites, or potential metabolites without a structural assignment. This study demonstrates that in some–but not all–cases, suspect screening analysis methods provide a means to rapidly identify and characterize metabolites of xenobiotic chemicals.

Small molecule drug metabolite synthesis and identification: why, when and how?

Methods to Profile the Macromolecular Targets of Small Compounds.

Analytical strategies for identifying drug metabolites

Academic foreign compound metabolism – 'quo vadis'?

Metabolomics: Bridging Chemistry and Biology in Drug Discovery and Development

The Current State of Biotransformation Science – Industry Survey of In Vitro and In Vivo Practices, Clinical Translation, and Future Trends

Identifying xenobiotic metabolites with in silico prediction tools and LCMS suspect screening analysis

Application of Mass Spectrometry for Metabolite Identification

Drug metabolism in drug discovery and development

Drugs from drugs: New chemical insights into a mature concept

Metabolomics in clinical and forensic toxicology, sports anti‐doping and veterinary residues

Exploring the Functional Roles of Small-Molecule Metabolites in Disease Research: Recent Advancements in Metabolomics

Metabolite profiling and characterization for medicinal herbal remedies.

Small molecule metabolites: discovery of biomarkers and therapeutic targets

Characterization of the Impact of Drug Metabolism on the Gas-Phase Structures of Drugs Using Ion Mobility-Mass Spectrometry.

The landscape of small-molecule prodrugs

Electrochemical generation of drug metabolites with applications in drug discovery and development

Enabling synthesis in fragment-based drug discovery (FBDD): microscale high-throughput optimisation of the medicinal chemist's toolbox reactions

Emerging applications of metabolomics in drug discovery and precision medicine

Metabolism of new drug modalities research advances - 2023 year in review

Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis